These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 12235571

  • 1. [Immunosuppressants and multiple sclerosis].
    Ruiz-Peña JL, Izquierdo-Ayuso G.
    Rev Neurol; ; 35(4):373-80. PubMed ID: 12235571
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH.
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
    Gonsette RE.
    Expert Opin Pharmacother; 2007 Jun; 8(8):1103-16. PubMed ID: 17516874
    [Abstract] [Full Text] [Related]

  • 7. Non-specific immunosuppressants in the treatment of multiple sclerosis.
    Confavreux C, Vukusic S.
    Clin Neurol Neurosurg; 2004 Jun; 106(3):263-9. PubMed ID: 15177781
    [Abstract] [Full Text] [Related]

  • 8. Cladribine as a therapeutic option in multiple sclerosis.
    Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP.
    Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cladribine for multiple sclerosis: review and current status.
    Sipe JC.
    Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
    [Abstract] [Full Text] [Related]

  • 11. New oral drugs for multiple sclerosis.
    Gasperini C, Ruggieri S.
    Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [Abstract] [Full Text] [Related]

  • 12. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B.
    Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [Abstract] [Full Text] [Related]

  • 13. [Non-specific immunosuppression and multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 1998 Sep; 154(8-9):629-34. PubMed ID: 9809379
    [Abstract] [Full Text] [Related]

  • 14. [Advances in the treatment of multiple sclerosis?].
    Tackenberg B, Himmerich H, Wellek A, Oertel WH, Sommer N.
    MMW Fortschr Med; 2007 May 21; 149 Suppl 2():51-5. PubMed ID: 17724968
    [Abstract] [Full Text] [Related]

  • 15. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M, Ghezzi A, Comi G.
    Neurol Sci; 2006 Mar 21; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [Abstract] [Full Text] [Related]

  • 16. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
    Ory S, Debouverie M, Le Page E, Pelletier J, Malikova I, Gout O, Roullet E, Vermersch P, Edan G.
    Rev Neurol (Paris); 2008 Dec 21; 164(12):1028-34. PubMed ID: 18808781
    [Abstract] [Full Text] [Related]

  • 17. The peculiar difficulties of therapeutic trials for multiple sclerosis.
    Myers LW, Ellison GW.
    Neurol Clin; 1990 Feb 21; 8(1):119-41. PubMed ID: 1690838
    [Abstract] [Full Text] [Related]

  • 18. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
    Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, Amato MP.
    J Neurol Sci; 2008 Mar 15; 266(1-2):25-30. PubMed ID: 17870094
    [Abstract] [Full Text] [Related]

  • 19. The limitations of immunosuppressant therapy in Multiple Sclerosis.
    Sedal L.
    J Clin Neurosci; 2000 Nov 15; 7(6):563-4; discussion 564-5. PubMed ID: 11029245
    [No Abstract] [Full Text] [Related]

  • 20. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
    Yeh EA, Weinstock-Guttman B.
    Neurology; 2009 Jun 16; 72(24):2064-5. PubMed ID: 19439721
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.